Pulmonx (NASDAQ:LUNG) Price Target Raised to $4.00

Key Points

• Stifel Nicolaus raised Pulmonx’s price target from $2.50 to $4.00 and maintained a Buy rating, implying 52.38% upside from the prior close. Analysts’ consensus rating is Moderate Buy, with an average target of $7.67.
• Pulmonx’s third-quarter results exceeded expectations: the company reported a $0.19 per-share loss versus the anticipated $0.26 loss, while revenue reached $22.84 million compared with the $21.93 million estimate. Management maintained its 2026 revenue outlook of $90 million to $92 million.
• Despite improving revenue and operating metrics, Pulmonx remains unprofitable, with a negative net margin and projected full-year loss. Executives sold shares to cover tax obligations, while institutional investors own 91.04% of the stock.

Pulmonx (NASDAQ:LUNG - Get Free Report) had its target price raised by stock analysts at Stifel Nicolaus from $2.50 to $4.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. Stifel Nicolaus's price objective points to a potential upside of 52.38% from the company's previous close.

A number of other brokerages also recently commented on LUNG. Weiss Ratings upgraded shares of Pulmonx from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 25th. Canaccord Genuity Group set a $5.00 target price on shares of Pulmonx in a research report on Wednesday. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $7.67.

Pulmonx Price Performance

Shares of NASDAQ LUNG traded up $0.65 during trading on Wednesday, reaching $2.62. The company had a trading volume of 5,371,230 shares, compared to its average volume of 495,513. The company has a current ratio of 4.32, a quick ratio of 3.52 and a debt-to-equity ratio of 0.95. Pulmonx has a twelve month low of $1.13 and a twelve month high of $2.77. The stock has a 50-day moving average price of $2.02 and a two-hundred day moving average price of $1.65. The stock has a market capitalization of $112.74 million, a PE ratio of -2.27 and a beta of 0.33.

Pulmonx (NASDAQ:LUNG - Get Free Report) last posted its quarterly earnings data on Tuesday, October 27th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.07. The business had revenue of $22.84 million for the quarter, compared to analyst estimates of $21.93 million. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%. As a group, sell-side analysts predict that Pulmonx will post -1.05 earnings per share for the current year.

Insider Activity

In other news, CEO Glendon French, III sold 41,882 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $2.26, for a total transaction of $94,653.32. Following the transaction, the chief executive officer directly owned 1,137,936 shares in the company, valued at $2,571,735.36. This represents a 3.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Srikanth Radhakrishnan sold 14,245 shares of the business's stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $2.26, for a total transaction of $32,193.70. Following the completion of the sale, the insider owned 316,994 shares of the company's stock, valued at approximately $716,406.44. The trade was a 4.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 78,340 shares of company stock valued at $177,048 in the last 90 days. 7.50% of the stock is currently owned by insiders.

Institutional Trading of Pulmonx

Several institutional investors have recently made changes to their positions in LUNG. Engineers Gate Manager LP raised its position in shares of Pulmonx by 11.5% in the 2nd quarter. Engineers Gate Manager LP now owns 62,589 shares of the company's stock worth $81,000 after buying an additional 6,438 shares during the period. Algert Global LLC increased its stake in Pulmonx by 15.2% during the second quarter. Algert Global LLC now owns 98,332 shares of the company's stock worth $128,000 after acquiring an additional 12,970 shares during the last quarter. ADAR1 Capital Management LLC increased its stake in Pulmonx by 5.4% during the first quarter. ADAR1 Capital Management LLC now owns 374,497 shares of the company's stock worth $483,000 after acquiring an additional 19,087 shares during the last quarter. R Squared Ltd purchased a new position in shares of Pulmonx in the 1st quarter worth about $26,000. Finally, Sei Investments Co. purchased a new position in shares of Pulmonx in the 1st quarter worth about $31,000. 91.04% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Pulmonx

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Q3 results exceeded expectations: Pulmonx reported adjusted earnings of a $0.19-per-share loss, narrower than the $0.26 loss analysts expected and improved from a $0.34 loss a year earlier. Revenue rose 6% year over year to $22.8 million, ahead of the $21.9 million consensus estimate. Pulmonx Corporation Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: Improving operating metrics: U.S. revenue increased 7% to $14.9 million, international revenue grew 5% to $7.9 million, gross margin reached 76%, and operating expenses declined 18% to $24.9 million. The company also maintained its full-year 2026 revenue outlook of $90 million to $92 million and operating-expense guidance of $108 million to $109 million. Pulmonx Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Buy rating reiterated: Canaccord maintained its Buy rating on LUNG, reinforcing the bullish interpretation of the earnings report. Canaccord Reiterates Buy Rating on Pulmonx
• Neutral Sentiment: Pulmonx ended September with $52.7 million in cash and reiterated its outlook, but it remains unprofitable and expects a full-year loss.
• Negative Sentiment: Reported insider-trading data showed no insider purchases and multiple executive sales over the past six months, a potential cautionary signal for investors.

Pulmonx Company Profile

Pulmonx Corporation is a medical device company focused on developing minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's technologies are designed to reduce hyperinflation in damaged portions of the lung and help improve breathing, exercise capacity and quality of life.

Pulmonx's primary product is the Zephyr Endobronchial Valve, a bronchoscopically implanted, one-way valve intended for certain patients with severe emphysema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.